Your session is about to expire
← Back to Search
Amino Acid
Oral L-Citrulline for Bronchopulmonary Dysplasia and Necrotizing Enterocolitis
N/A
Recruiting
Led By Estelle Gauda, MD
Research Sponsored by The Hospital for Sick Children
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Post-menstrual age (PMA) ≥ 34 weeks
Echocardiographic evidence of PH for infants with BPD+PH
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
Study Summary
This trial will study if supplementing preterm infants with an amino acid can help protect from serious diseases, like NEC and BPD.
Who is the study for?
This trial is for preterm infants born at or before 30 weeks, currently older than 34 weeks post-menstrual age. It's specifically for those with Bronchopulmonary Dysplasia (BPD) and/or Pulmonary Hypertension (PH), who need breathing support. Infants must have a Respiratory Severity Score (RSS) over 2 and be on ventilation more than half the day.Check my eligibility
What is being tested?
The study tests L-Citrulline supplementation in these infants to prevent inflammation that can lead to severe lung conditions like BPD±PH and intestinal issues like Necrotizing Enterocolitis (NEC). The safety of this treatment and how it affects the body will be closely monitored.See study design
What are the potential side effects?
As this trial aims to establish safety, potential side effects are not fully known but may include reactions related to digestion, growth, or metabolism given L-Citrulline's role in the body.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My baby is at least 34 weeks in adjusted age since conception.
Select...
My baby has heart issues related to lung problems.
Select...
I've been on a ventilator for more than 12 hours a day for at least 2 days.
Select...
I was born at or before 30 weeks of pregnancy.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Safety of oral L-Citrulline administration
Secondary outcome measures
Association of blood pressure as one of the PD outcomes with maximum L-CIT concentration (Cmax)
Association of blood pressure with minimum L-CIT concentration (Cmin)
Association of blood pressure with the area under the concentration time curve (AUC) for L-CIT
+19 moreSide effects data
From 2021 Phase 2 trial • 65 Patients • NCT045703849%
Infusion Site Reaction
6%
Deep Vein Thrombosis
6%
Dyspnoea
6%
Clostridium Difficile Infection
6%
Urinary Tract Infection
3%
Staphylococcal Sepsis; Alpha Haemolytic Streptococcal Infection
3%
Pain In Extremity
3%
Skin Wound
3%
Acute kidney injury
3%
Cardiac failure; metabolic acidosis
3%
Chest pain; Dyspnoea; COVID-19
3%
Intracranial hemorrhage
3%
Acute Myocardial Infarction
3%
Status epilepticus
3%
Syncope
3%
Enterococcal Infection
3%
Enterococcus Test Positive
3%
Epistaxis
3%
Hypoglycaemia
3%
Hypoxia
3%
Tachycardia
3%
Ventricular Extrasystoles
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo Arm
IV L-Citrulline (Turnobi) Arm
Trial Design
2Treatment groups
Experimental Treatment
Group I: Surgical NECExperimental Treatment1 Intervention
Arm 2: sNEC
A total of 18-36 infants with Stage III NEC; 6-12 at each dose level of oral dosage form of L-Citrulline. (75, 150 or 225 mg/kg/day divided q6 hours)
Dose Level 1 = 75 mg/kg/day Dose Level 2 = 150 mg/kg/day Dose Level 3 = 225 mg/kg/day
Group II: BPD±PHExperimental Treatment1 Intervention
Arm 1: BPD±PH
Total of 12-24 infants; 6-12 at each dose level of oral dosage form of L-Citrulline. (300 or 500 mg/kg/day divided q6 hours).
Dose Level 1 = 300 mg/kg/day Dose Level 2 = 500 mg/kg/day
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
L-Citrulline
2023
Completed Phase 2
~340
Find a Location
Who is running the clinical trial?
The Hospital for Sick ChildrenLead Sponsor
692 Previous Clinical Trials
6,946,540 Total Patients Enrolled
2 Trials studying Bronchopulmonary Dysplasia
331 Patients Enrolled for Bronchopulmonary Dysplasia
Estelle Gauda, MDPrincipal InvestigatorDivision Head, Division of Neonatology
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the upper boundary of individuals participating in this experiment?
"Affirmative. According to information listed on clinicaltrials.gov, this research project is currently enrolling participants and was published November 1st 2023 with the latest update dated November 28th of that same year. A total of 60 individuals are being sought out for participation at a single medical facility."
Answered by AI
Does this clinical trial currently have an open enrollment period?
"Presently, this clinical trial is recruiting participants according to the data available on clinicaltrials.gov. The study was first published on November 1st 2023 and recently updated at the end of that month."
Answered by AI
Does the current research study permit individuals aged 50 or older to participate?
"This medical trial's inclusion criteria requires that patients are younger than 6 months of age. Furthermore, there are 71 studies for minors and 90 experiments dedicated to senior citizens."
Answered by AI
Who meets the criteria for participating in this research endeavor?
"This research trial has a total recruitment of 60 individuals, who must have bronchopulmonary dysplasia and be between the ages of 1 Month to 6 Months."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger